Health Affairs December 3, 2025
In November 2025, the White House announced that drug manufacturers, Eli Lilly (makers of Zepbound and Orforglipron) and Novo Nordisk (makers of Ozempic and Wegovy), will substantially reduce the price of weight loss medications under the Most Favored Nation (MFN) policy that requires that the United States pay no more for prescription medications than the lowest price paid by other high-income countries. The new announcement has the potential to make highly effective Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) therapies more affordable for millions of Americans diagnosed with obesity.
While details are forthcoming, it is noteworthy that the price will vary by the specific drug, the dose prescribed, and the payer. For example:
- Medicare will pay $245 per month for...
Today's Sponsors
Today's Sponsor